We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
27
Aug 2026
Researchers have identified a broad range of biological properties in pomegranate with potential for use in medical applications, including antimicrobial, antiparasitic, antioxidant, immunomodulatory, antidiabetic, anti-inflammatory, liver-supporting, and wound-healing effects.
27
Aug 2026
When researchers at Lund University investigated how the molecule UM171 works, a molecule used to make blood stem cells multiply, they made an unexpected connection.
27
Aug 2026
The great majority of people taking part in a study lost weight by following personalised nutritional insights, rather than going on a calorie counting or restrictive diet, reveal findings from a new study.
27
Aug 2026
Mayo Clinic is a clinical collaborator on an award of up to $27.7 million from the Advanced Research Projects Agency for Health (ARPA-H) to help develop affordable, scalable gene-editing therapies for children with rare inherited immune disorders.